BCHE and Alzheimer disease: Whereas cholinesterase inhibitors such as donepezil, galantamine, or rivastigmine, together with memantine, a noncompetitive antagonist of the NMDA receptor, are presently at the forefront of clinical interventions for AD, new insights are bringing other drugs targeting nAChRs to center stage [109].